Every year, the American Society of Clinical Oncology (ASCO) Annual Meeting gathers oncologists from around the globe to unveil the latest advancements in cancer research. This year, several significant updates in prostate cancer research emerged, potentially leading to more personalized and effective treatment options. We’ve gathered some of the key innovations to help you stay informed below.
A new artificial-intelligence (AI) tool can determine which patients with prostate cancer are likely to benefit from abiraterone. Abiraterone is an oral drug that’s been shown to halve the risk of death for men with high-risk prostate cancer that hasn’t spread. The development of this AI tool means oncologists can more accurately identify men who can benefit from abiraterone compared to those who would benefit more from the standard treatment.
Results from the phase III ARANOTE trial showed that adding darolutamide to androgen deprivation therapy (ADT) improved quality of life for patients with metastatic hormone-sensitive prostate cancer. Patients had less pain and improved overall well-being compared to those who received ADT alone. This data is significant because it highlights darolutamide as the first androgen receptor antagonist to show clinically meaningful improvements in both pain progression and overall well-being.
The phase III AMPLITUDE trial found that adding niraparib to the standard treatment of abiraterone and prednisone helped slow cancer growth in people with metastatic castration-sensitive prostate cancer (mCSPC) with homologous recombination repair (HRR) gene alterations. This data is important because while niraparib is already approved for HRR-altered metastatic castration-resistant prostate cancer, these results suggest adding niraparib earlier may be beneficial.
Data from the phase III PrTK03 trial showed that adding CAN-2409 with valacyclovir to radiation therapy reduced the risk of recurrence or death by 30% in patients with intermediate to high-risk, localized prostate cancer. These findings are significant because CAN-2409 may offer a first new treatment option for localized prostate cancer, something that hasn’t changed in 20 years.
The ARCHES clinical trial examined enzalutamide plus androgen deprivation therapy (ADT) in patients with metastatic castration-sensitive prostate cancer (mCSPC). After five years, this combination treatment reduced the risk of death by 34% and delayed cancer progression by 61% compared to the placebo group. These results suggest that adding enzalutamide can lead to long-term survival benefits.
Stay informed on the latest news in prostate cancer research and download the Outcomes4Me app. Enable notifications so we can send you important updates.
